Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222

Shu-Hsing Cheng, Yi-Chun Lin, Cheng-Pin Chen, Chien-Yu Cheng
doi: https://doi.org/10.1101/2021.12.10.21267574

Article Information

doi 
https://doi.org/10.1101/2021.12.10.21267574
History 
  • January 18, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Shu-Hsing Cheng1,2,
  2. Yi-Chun Lin1,
  3. Cheng-Pin Chen1,3 and
  4. Chien-Yu Cheng*,1,4
  1. 1Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
  2. 2School of Public Health, Taipei Medical University, Taipei, Taiwan
  3. 3Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University
  4. 4School of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan
  1. ↵*Corresponding author: s841060{at}gm.ym.edu.tw
Back to top
Posted January 18, 2022.
Download PDF
Data/Code
Email
Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222
Shu-Hsing Cheng, Yi-Chun Lin, Cheng-Pin Chen, Chien-Yu Cheng
medRxiv 2021.12.10.21267574; doi: https://doi.org/10.1101/2021.12.10.21267574
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area